#Biofrontera #exercises #acquired #options #full
WOBURN, Mass., Nov. 8, 2022 (GLOBE NEWSWIRE) — Biofrontera inc (Nasdaq: BRI) a biopharmaceutical company specializing in the marketing of dermatological products, today announced the full exercise of options to purchase 2,623,365 common shares of Biofrontera AG. These options were acquired under a private exchange agreement announced October 31, 2022 and exercised at no additional cost. In addition, Biofrontera Inc. announced the purchase of a further 1,601,318 shares in Biofrontera AG.
As a result of this transaction, Biofrontera Inc. now owns 4,224,683 shares, representing 7.45% of Biofrontera AG’s outstanding ordinary shares.
“Biofrontera Inc. is responsible for the distribution of Biofrontera AG products in the world’s largest dermatology market, is the main driver of its growth and its largest source of income. The full exercise of these options strengthens and directs the mutually beneficial relationship between our two…
Read on GNW: Biofrontera Inc. exercises recently acquired options in full
